<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>BioScreening.net</title>
	<atom:link href="http://www.bioscreening.net/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.bioscreening.net</link>
	<description>BioScreening news and events</description>
	<lastBuildDate>Mon, 30 Aug 2010 18:01:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0</generator>
		<item>
		<title>Novel &#8216;Antisense&#8217; Therapies Protect Primates from Lethal Ebola and Marburg Viruses</title>
		<link>http://www.bioscreening.net/2010/08/30/novel-antisense-therapies-protect-primates-from-lethal-ebola-and-marburg-viruses/</link>
		<comments>http://www.bioscreening.net/2010/08/30/novel-antisense-therapies-protect-primates-from-lethal-ebola-and-marburg-viruses/#comments</comments>
		<pubDate>Mon, 30 Aug 2010 18:01:35 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Reports]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1030</guid>
		<description><![CDATA[ScienceDaily (Aug. 23, 2010) — New studies show that treatments targeting specific viral genes protected monkeys infected with deadly Ebola or Marburg viruses. Furthermore, the animals were protected even when therapeutics were administered one hour after exposure &#8212; suggesting the approach holds promise for treating accidental infections in laboratory or hospital settings. See Also: Health [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/08/30/novel-antisense-therapies-protect-primates-from-lethal-ebola-and-marburg-viruses/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Molecular Target for Screening:  G-Protein-Coupled Receptors</title>
		<link>http://www.bioscreening.net/2010/08/19/molecular-target-for-screening-g-protein-coupled-receptors/</link>
		<comments>http://www.bioscreening.net/2010/08/19/molecular-target-for-screening-g-protein-coupled-receptors/#comments</comments>
		<pubDate>Thu, 19 Aug 2010 19:10:41 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Compound Libraries]]></category>
		<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[Genomics & Pharmacogenomics]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Targeted Libraries]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1021</guid>
		<description><![CDATA[Newark, DE. August, 2010 – Press Release &#8211; TimTec, LLC. &#8211; Molecular Target for Screening:  G-Protein-Coupled Receptors, ActiTarg-G G-Protein-Coupled Receptors are the largest gene families in the human genome and, rightfully so, have become the leading molecular target in 2008. In 2009 SBS April meeting in Lille, France, followed-up with screening trends report stating that  [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/08/19/molecular-target-for-screening-g-protein-coupled-receptors/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Actelion obtains option to acquire privately-held Trophos</title>
		<link>http://www.bioscreening.net/2010/08/05/actelion-obtains-option-to-acquire-privately-held-trophos/</link>
		<comments>http://www.bioscreening.net/2010/08/05/actelion-obtains-option-to-acquire-privately-held-trophos/#comments</comments>
		<pubDate>Thu, 05 Aug 2010 18:04:08 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Mergers and Acquisitions]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1016</guid>
		<description><![CDATA[Late-stage Phase III compound in Amyotrophic Lateral Sclerosis to report data in late 2011 – Novel therapeutic approach to be further explored in drug discovery collaboration ALLSCHWIL, SWITZERLAND and MARSEILLE, FRANCE – 20 July 2010 – Actelion Ltd (SIX: ATLN) and privately-held Trophos SA announced today that they have entered into a binding agreement whereby [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/08/05/actelion-obtains-option-to-acquire-privately-held-trophos/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Screen for molecules that inhibit formation of A-beta oligomers</title>
		<link>http://www.bioscreening.net/2010/08/05/screen-for-molecules-that-inhibit-formation-of-a-beta-oligomers/</link>
		<comments>http://www.bioscreening.net/2010/08/05/screen-for-molecules-that-inhibit-formation-of-a-beta-oligomers/#comments</comments>
		<pubDate>Thu, 05 Aug 2010 18:00:42 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Alzheimer's disease]]></category>
		<category><![CDATA[Compound Screening]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1014</guid>
		<description><![CDATA[Alzheimer’s disease (AD) is a devastating neurological disorder characterized by the deposition of aggregated proteins in the brain in the form of extracellular beta-amyloid in senile plaques and intracellular tau in neurofibrillary tangles. A current approach towards treatment of Alzheimer’s disease is by using inhibitors of amyloid beta aggregation. Current screening protocols for inhibitors of [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/08/05/screen-for-molecules-that-inhibit-formation-of-a-beta-oligomers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nine U.S. Health Research Centers to Receive $255 Million</title>
		<link>http://www.bioscreening.net/2010/07/22/nine-us-health-research-centers-to-receive-255-million/</link>
		<comments>http://www.bioscreening.net/2010/07/22/nine-us-health-research-centers-to-receive-255-million/#comments</comments>
		<pubDate>Thu, 22 Jul 2010 19:51:13 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Business and Investment]]></category>
		<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Research Projects]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/22/nine-us-health-research-centers-to-receive-255-million/</guid>
		<description><![CDATA[Nine health research centers have received funds to develop ways to reduce the time it takes for clinical research to become treatments for patients. The funds were awarded as part of the Clinical and Translational Science Awards (CTSA) program which is led by the National Center for Research Resources (NCRR), part of the National Institutes [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/22/nine-us-health-research-centers-to-receive-255-million/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BioFocus and University of Bristol enter drug discovery collaboration in chronic pain</title>
		<link>http://www.bioscreening.net/2010/07/20/biofocus-and-university-of-bristol-enter-drug-discovery-collaboration-in-chronic-pain/</link>
		<comments>http://www.bioscreening.net/2010/07/20/biofocus-and-university-of-bristol-enter-drug-discovery-collaboration-in-chronic-pain/#comments</comments>
		<pubDate>Tue, 20 Jul 2010 18:28:14 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Collaborations]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/20/biofocus-and-university-of-bristol-enter-drug-discovery-collaboration-in-chronic-pain/</guid>
		<description><![CDATA[Saffron Walden and Bristol, UK; 16 July 2010 â€“ BioFocus and the University of Bristol today announced a new drug discovery collaboration aimed at developing treatments for chronic pain associated with diabetes (diabetic neuropathic pain).Â  BioFocus will provide hit-to-lead and lead optimization services for a Wellcome Trust funded program at the University of Bristol.Â  Total [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/20/biofocus-and-university-of-bristol-enter-drug-discovery-collaboration-in-chronic-pain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>NIH Prolongs Compound-Management Arrangement with Galapagos Until End of 2012</title>
		<link>http://www.bioscreening.net/2010/07/20/nih-prolongs-compound-management-arrangement-with-galapagos-until-end-of-2012/</link>
		<comments>http://www.bioscreening.net/2010/07/20/nih-prolongs-compound-management-arrangement-with-galapagos-until-end-of-2012/#comments</comments>
		<pubDate>Tue, 20 Jul 2010 18:22:04 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Collaborations]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/20/nih-prolongs-compound-management-arrangement-with-galapagos-until-end-of-2012/</guid>
		<description><![CDATA[NIH has extended its agreement with Galapagos&#8217; service division, BioFocus, for the operation of the Molecular Libraries Small Molecule Repository (MLSMR) through December 2012. Galapagos will thus be eligible to receive up to $8.6 million over the course of the two-year extension. The NIH MLSMR collects samples for high-throughput biological screening and distributes them to [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/20/nih-prolongs-compound-management-arrangement-with-galapagos-until-end-of-2012/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Aquapharm and AMRI Enter into a Novel Marine Chemistry Collaboration</title>
		<link>http://www.bioscreening.net/2010/07/12/aquapharm-and-amri-enter-into-a-novel-marine-chemistry-collaboration/</link>
		<comments>http://www.bioscreening.net/2010/07/12/aquapharm-and-amri-enter-into-a-novel-marine-chemistry-collaboration/#comments</comments>
		<pubDate>Mon, 12 Jul 2010 18:24:24 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Collaborations]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/12/aquapharm-and-amri-enter-into-a-novel-marine-chemistry-collaboration/</guid>
		<description><![CDATA[Aquapharm Biodiscovery, a leading marine biotechnology company, announced today it has signed a research agreement with Albany Molecular Research  to identify novel drug-like compounds and scaffolds with anti-microbial and anti-inflammatory activity from Aquapharm&#8217;s marine natural products library derived from its extensive collection of marine micro-organisms.Under the terms of this agreement, drawing on its substantial experience [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/12/aquapharm-and-amri-enter-into-a-novel-marine-chemistry-collaboration/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Volatile Organic Compounds (VOCs) on the Gulf Coastline</title>
		<link>http://www.bioscreening.net/2010/07/12/volatile-organic-compounds-vocs-on-the-gulf-coastline/</link>
		<comments>http://www.bioscreening.net/2010/07/12/volatile-organic-compounds-vocs-on-the-gulf-coastline/#comments</comments>
		<pubDate>Mon, 12 Jul 2010 18:22:42 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Events]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/12/volatile-organic-compounds-vocs-on-the-gulf-coastline/</guid>
		<description><![CDATA[Resource: EPA â€“ United States Environmental Protection Agency Volatile Organic Compounds (VOCs) on the Gulf Coastline EPA is analyzing air samples for volatile organic compounds (VOCs) â€“ including specifically, benzene, ethylbenzene, toluene, and xylene. EPA is sampling for these pollutants because they are present in oil and because, at elevated concentrations, they may cause health [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/12/volatile-organic-compounds-vocs-on-the-gulf-coastline/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The NIH Molecular Libraries Program: Identifying Chemical Probes for New Medicines</title>
		<link>http://www.bioscreening.net/2010/07/12/the-nih-molecular-libraries-program-identifying-chemical-probes-for-new-medicines/</link>
		<comments>http://www.bioscreening.net/2010/07/12/the-nih-molecular-libraries-program-identifying-chemical-probes-for-new-medicines/#comments</comments>
		<pubDate>Mon, 12 Jul 2010 18:12:01 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[HT Screening]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/12/the-nih-molecular-libraries-program-identifying-chemical-probes-for-new-medicines/</guid>
		<description><![CDATA[Alice McCarthy In 2003, several program leaders within theÂ National Institutes of Health (NIH) recognized that the results from the recently completed Human Genome Project were a launching pad for further study. Now that scientists knew the genome, how could they determine gene function? In particular, how could scientists find specific biological pathways and targets that [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/12/the-nih-molecular-libraries-program-identifying-chemical-probes-for-new-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>AstraZeneca signs malaria drug research agreement</title>
		<link>http://www.bioscreening.net/2010/07/12/astrazeneca-signs-malaria-drug-research-agreement/</link>
		<comments>http://www.bioscreening.net/2010/07/12/astrazeneca-signs-malaria-drug-research-agreement/#comments</comments>
		<pubDate>Mon, 12 Jul 2010 18:10:26 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/12/astrazeneca-signs-malaria-drug-research-agreement/</guid>
		<description><![CDATA[* JV will allow screening of 500,000 compounds * Malaria kills up to 1 million people a year * Shares up 0.2 percent LONDON, June 28 (Reuters) &#8211; Anglo-Swedish drugmaker AstraZeneca said it was opening up around 500,000 of its chemical compounds to the Medicines for Malaria Venture (MMV) to help speed up development of [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/12/astrazeneca-signs-malaria-drug-research-agreement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Increasing The Odds Of Hit Iidentification By Screening Against Receptor Homologs</title>
		<link>http://www.bioscreening.net/2010/07/12/increasing-the-odds-of-hit-iidentification-by-screening-against-receptor-homologs/</link>
		<comments>http://www.bioscreening.net/2010/07/12/increasing-the-odds-of-hit-iidentification-by-screening-against-receptor-homologs/#comments</comments>
		<pubDate>Mon, 12 Jul 2010 14:31:28 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/12/increasing-the-odds-of-hit-iidentification-by-screening-against-receptor-homologs/</guid>
		<description><![CDATA[Abstractâ€” Increasing the odds of hit identification in screening is of significance for drug discovery. The odds for finding a hit are closely related either to the diversity of libraries or to the availability of focused libraries. There are no truly diverse libraries and it is difficult to design focused libraries without sufficient information. Hence [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/12/increasing-the-odds-of-hit-iidentification-by-screening-against-receptor-homologs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Speeding up drug screening</title>
		<link>http://www.bioscreening.net/2010/07/12/915/</link>
		<comments>http://www.bioscreening.net/2010/07/12/915/#comments</comments>
		<pubDate>Mon, 12 Jul 2010 14:28:39 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[HT Screening]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/12/915/</guid>
		<description><![CDATA[Box 1: Speeding up drug screening Whole-cell assays allow new drugs to be screened for efficacy without knowing the molecular targets. High-throughput screens (HTSs) are vital in the quest for new compounds, but until recently have been lacking for Chagas disease. At the Swiss Tropical and Public Health Institute, Reto Brun provides a &#8216;gold standard&#8217; [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/12/915/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Over 5 million compounds screened</title>
		<link>http://www.bioscreening.net/2010/07/12/over-5-million-compounds-screened/</link>
		<comments>http://www.bioscreening.net/2010/07/12/over-5-million-compounds-screened/#comments</comments>
		<pubDate>Mon, 12 Jul 2010 13:57:11 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/12/over-5-million-compounds-screened/</guid>
		<description><![CDATA[Data from three projects released into the public domain In its search for new molecules against malaria, MMV has so far supported the screening of more than 5 million compounds for their potential activity against the malaria parasite. Three partners of the MMV-supported early discovery projects have gone a step further and released the data [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/12/over-5-million-compounds-screened/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>NIH High-Throughput Screening Identifies Candidate Medicines for CMT</title>
		<link>http://www.bioscreening.net/2010/07/12/nih-high-throughput-screening-identifies-candidate-medicines-for-cmt/</link>
		<comments>http://www.bioscreening.net/2010/07/12/nih-high-throughput-screening-identifies-candidate-medicines-for-cmt/#comments</comments>
		<pubDate>Mon, 12 Jul 2010 13:55:50 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[HT Screening]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/12/nih-high-throughput-screening-identifies-candidate-medicines-for-cmt/</guid>
		<description><![CDATA[The NIH has completed the high-throughput screening program. Working with a chemical library of more than 350,000 compounds, the NIH screened each compound at approximately 7 different dosage levels-resulting in more than 2 million unique screens. Out of the 4000 FDA approved drugs, 10 &#8220;hits&#8221; or candidate medicines were found. At this point in time, [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/12/nih-high-throughput-screening-identifies-candidate-medicines-for-cmt/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Asterand Signs Agreement with Amylin Pharmaceuticals BioMAP(R) Platform will screen peptides for therapeutic potential</title>
		<link>http://www.bioscreening.net/2010/07/12/asterand-signs-agreement-with-amylin-pharmaceuticals-biomapr-platform-will-screen-peptides-for-therapeutic-potential/</link>
		<comments>http://www.bioscreening.net/2010/07/12/asterand-signs-agreement-with-amylin-pharmaceuticals-biomapr-platform-will-screen-peptides-for-therapeutic-potential/#comments</comments>
		<pubDate>Mon, 12 Jul 2010 13:48:22 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Business and Investment]]></category>
		<category><![CDATA[Collaborations]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/12/asterand-signs-agreement-with-amylin-pharmaceuticals-biomapr-platform-will-screen-peptides-for-therapeutic-potential/</guid>
		<description><![CDATA[Asterand plc /quotes/comstock/23s!e:atd (UK:ATD 13.25, 0.00, 0.00%) , a leading provider of human tissue and human tissue-based research services to pharmaceutical and biotechnology companies engaged in drug discovery, today announces that its subsidiary BioSeek, LLC, a pioneer in the application of predictive human biology to drug discovery, has signed a one-year collaboration agreement with Amylin [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/12/asterand-signs-agreement-with-amylin-pharmaceuticals-biomapr-platform-will-screen-peptides-for-therapeutic-potential/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Increased R&amp;D Efforts Are Overcoming Obstacles and Showing Potential</title>
		<link>http://www.bioscreening.net/2010/07/12/911/</link>
		<comments>http://www.bioscreening.net/2010/07/12/911/#comments</comments>
		<pubDate>Mon, 12 Jul 2010 13:46:17 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[HT Screening]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/12/911/</guid>
		<description><![CDATA[Ion channels make good drug targetsâ€”they reside on the cell surface and are fast switching mechanisms. They act like cell transistors, controlling many cell processes. There are close to 500 types of ion channels, yet many remain undiscovered. This was mainly attributed to technology restraints, however, with the recent introduction of HT patch clamping, as [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/12/911/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TimTec Launches Division of Organic Synthesis and Medicinal Chemistry Contract Research Services</title>
		<link>http://www.bioscreening.net/2010/07/08/timtec-launches-division-of-organic-synthesis-and-medicinal-chemistry-contract-research-services/</link>
		<comments>http://www.bioscreening.net/2010/07/08/timtec-launches-division-of-organic-synthesis-and-medicinal-chemistry-contract-research-services/#comments</comments>
		<pubDate>Fri, 09 Jul 2010 03:39:07 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[ADMET Studies]]></category>
		<category><![CDATA[Business and Investment]]></category>
		<category><![CDATA[Drug-Like Compounds]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Research Projects]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/08/timtec-launches-division-of-organic-synthesis-and-medicinal-chemistry-contract-research-services/</guid>
		<description><![CDATA[Newark, DE, July 8, 2010 Press Release &#8211; TimTec, LLC is pleased to announce the launching of the new Division that manages Organic Synthesis and Medicinal Chemistry Contract Research Services. The emergence of the division is an evolutionarily progression for TimTecs business development. The company has been known for its expertise in organic chemistry design [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/08/timtec-launches-division-of-organic-synthesis-and-medicinal-chemistry-contract-research-services/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Optimer Pharmaceuticals Receives Milestone Payment From Cempra for Next-Generation Macrolide Antibiotic</title>
		<link>http://www.bioscreening.net/2010/07/08/optimer-pharmaceuticals-receives-milestone-payment-from-cempra-for-next-generation-macrolide-antibiotic/</link>
		<comments>http://www.bioscreening.net/2010/07/08/optimer-pharmaceuticals-receives-milestone-payment-from-cempra-for-next-generation-macrolide-antibiotic/#comments</comments>
		<pubDate>Fri, 09 Jul 2010 03:02:48 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[BioInformatics]]></category>
		<category><![CDATA[Business and Investment]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/08/optimer-pharmaceuticals-receives-milestone-payment-from-cempra-for-next-generation-macrolide-antibiotic/</guid>
		<description><![CDATA[SAN DIEGO, July 8 /PRNewswire-FirstCall/ &#8211; Optimer Pharmaceuticals, Inc. today announced it has received a $500,000 milestone payment from Cempra Pharmaceuticals, Inc. pursuant to the terms of a licensing agreement between the companies. Â The milestone payment was made as a result of Cempra&#8217;s continuing development of a next-generation macrolide (CEM-101) for the treatment of respiratory [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/08/optimer-pharmaceuticals-receives-milestone-payment-from-cempra-for-next-generation-macrolide-antibiotic/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ranbaxy to transfer drug discovery unit to Daiichi Sankyo</title>
		<link>http://www.bioscreening.net/2010/07/08/ranbaxy-to-transfer-drug-discovery-unit-to-daiichi-sankyo/</link>
		<comments>http://www.bioscreening.net/2010/07/08/ranbaxy-to-transfer-drug-discovery-unit-to-daiichi-sankyo/#comments</comments>
		<pubDate>Fri, 09 Jul 2010 02:54:19 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Asia]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/08/ranbaxy-to-transfer-drug-discovery-unit-to-daiichi-sankyo/</guid>
		<description><![CDATA[Jul 06, 2010 (Datamonitor via COMTEX) &#8211; Daiichi Sankyo and Ranbaxy Laboratories, a research based pharmaceutical company, have announced that Ranbaxy&#8217;s new drug discovery research, or NDDR, has been transferred to Daiichi Sankyo India Pharma as part of the strategy to strengthen the global R&#038;D structure of the Daiichi Sankyo Group. The transaction has been [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/08/ranbaxy-to-transfer-drug-discovery-unit-to-daiichi-sankyo/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
